LINE-1 CfDNA Methylation As an Emerging Biomarker in Solid Cancers

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Nov 27

PMID 39594682

Authors

Ugur Gezer

Emre Ozgur

Ebru E Yoruker

Eleni Polatoglou

Stefan Holdenrieder

Abel Bronkhorst

Affiliations

Soon will be listed here.

Abstract

Epigenetic dysregulation is a hallmark of many human malignancies, with DNA methylation being a primary mechanism influencing gene expression and maintaining genomic stability. Genome-wide hypomethylation, characteristic of many cancers, is partly attributed to the demethylation of repetitive elements, including LINE-1, a prevalent non-LTR retrotransposon. The methylation status of LINE-1 is closely associated with overall genomic methylation levels in tumors. cfDNA comprises extracellular DNA fragments found in bodily fluids such as plasma, serum, and urine, offering a dynamic snapshot of the genetic and epigenetic landscape of tumors. This real-time sampling provides a minimally invasive avenue for cancer diagnostics, prognostics, and monitoring. The methylation status of LINE-1 in cfDNA has emerged as a promising biomarker, with several studies highlighting its potential in diagnosing and predicting outcomes in cancer patients. Recent research also suggests that cfDNA-based LINE-1 methylation analysis could serve as a valuable tool in evaluating the efficacy of cancer therapies, including immunotherapy. The growing clinical significance of cfDNA calls for a closer examination of its components, particularly repetitive elements like LINE-1. Despite their importance, the role of LINE-1 elements in cfDNA has not been thoroughly gauged. We aim to address this gap by reviewing the current literature on LINE-1 cfDNA assays, focusing on their potential applications in diagnostics and disease monitoring.

References

Ponomaryova A, Rykova E, Solovyova A, Tarasova A, Kostromitsky D, Dobrodeev A . Dynamic Changes in Circulating Methylated Markers in Response to Antitumor Therapy of Rectal Cancer. J Gastrointest Cancer. 2024; 55(3):1190-1198. DOI: 10.1007/s12029-024-01066-y. View

Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D . LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics. 2009; 4(3):176-84. PMC: 2848123. DOI: 10.4161/epi.4.3.8694. View

Nell R, van Steenderen D, Menger N, Weitering T, Versluis M, van der Velden P . Quantification of DNA methylation independent of sodium bisulfite conversion using methylation-sensitive restriction enzymes and digital PCR. Hum Mutat. 2020; 41(12):2205-2216. PMC: 7756443. DOI: 10.1002/humu.24111. View

Ramzy I, Omran D, Hamad O, Shaker O, Abboud A . Evaluation of serum LINE-1 hypomethylation as a prognostic marker for hepatocellular carcinoma. Arab J Gastroenterol. 2011; 12(3):139-42. DOI: 10.1016/j.ajg.2011.07.002. View

Slee R, Steiner C, Herbert B, Vance G, Hickey R, Schwarz T . Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability. Oncogene. 2011; 31(27):3244-53. DOI: 10.1038/onc.2011.502. View

Jafri M, Ansari S, Alqahtani M, Shay J . Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med. 2016; 8(1):69. PMC: 4915101. DOI: 10.1186/s13073-016-0324-x. View

Yang A, Estecio M, Doshi K, Kondo Y, Tajara E, Issa J . A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res. 2004; 32(3):e38. PMC: 373427. DOI: 10.1093/nar/gnh032. View

Ponomaryova A, Cherdyntseva N, Bondar A, Dobrodeev A, Zavyalov A, Tuzikov S . [Dynamics of LINE-1 Retrotransposon Methylation Levels in Circulating DNA from Lung Cancer Patients Undergoing Antitumor Therapy]. Mol Biol (Mosk). 2017; 51(4):622-628. DOI: 10.7868/S0026898417040140. View

Ikeda K, Shiraishi K, Eguchi A, Shibata H, Yoshimoto K, Mori T . Long interspersed nucleotide element 1 hypomethylation is associated with poor prognosis of lung adenocarcinoma. Ann Thorac Surg. 2013; 96(5):1790-4. DOI: 10.1016/j.athoracsur.2013.06.035. View

10.

Bronkhorst A, Ungerer V, Oberhofer A, Gabriel S, Polatoglou E, Randeu H . New Perspectives on the Importance of Cell-Free DNA Biology. Diagnostics (Basel). 2022; 12(9). PMC: 9497998. DOI: 10.3390/diagnostics12092147. View

11.

Arayataweegool A, Srisuttee R, Mahattanasakul P, Tangjaturonsasme N, Kerekhanjanarong V, Kitkumthorn N . Head and neck squamous cell carcinoma drives long interspersed element-1 hypomethylation in the peripheral blood mononuclear cells. Oral Dis. 2018; 25(1):64-72. DOI: 10.1111/odi.12944. View

12.

Van Paemel R, De Koker A, Caggiano C, Morlion A, Mestdagh P, De Wilde B . Genome-wide study of the effect of blood collection tubes on the cell-free DNA methylome. Epigenetics. 2020; 16(7):797-807. PMC: 8216177. DOI: 10.1080/15592294.2020.1827714. View

13.

Sanchez C, Roch B, Mazard T, Blache P, Al Amir Dache Z, Pastor B . Circulating nuclear DNA structural features, origins, and complete size profile revealed by fragmentomics. JCI Insight. 2021; 6(7). PMC: 8119211. DOI: 10.1172/jci.insight.144561. View

14.

Heitzer E, Auinger L, Speicher M . Cell-Free DNA and Apoptosis: How Dead Cells Inform About the Living. Trends Mol Med. 2020; 26(5):519-528. DOI: 10.1016/j.molmed.2020.01.012. View

15.

Ponomaryova A, Rykova E, Gervas P, Cherdyntseva N, Mamedov I, Azhikina T . Aberrant Methylation of LINE-1 Transposable Elements: A Search for Cancer Biomarkers. Cells. 2020; 9(9). PMC: 7563416. DOI: 10.3390/cells9092017. View

16.

Teodoridis J, Strathdee G, Brown R . Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat. 2004; 7(4-5):267-78. DOI: 10.1016/j.drup.2004.06.005. View

17.

Nishiyama A, Nakanishi M . Navigating the DNA methylation landscape of cancer. Trends Genet. 2021; 37(11):1012-1027. DOI: 10.1016/j.tig.2021.05.002. View

18.

Levin H, Moran J . Dynamic interactions between transposable elements and their hosts. Nat Rev Genet. 2011; 12(9):615-27. PMC: 3192332. DOI: 10.1038/nrg3030. View

19.

Mima K, Nowak J, Qian Z, Cao Y, Song M, Masugi Y . Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival. Oncotarget. 2016; 7(34):55098-55109. PMC: 5342404. DOI: 10.18632/oncotarget.10398. View

20.

Lossi L, Castagna C, Merighi A . An Overview of the Epigenetic Modifications in the Brain under Normal and Pathological Conditions. Int J Mol Sci. 2024; 25(7). PMC: 11011998. DOI: 10.3390/ijms25073881. View